From Time to time patients are asked to participate in market research for which there is remuneration. We fielded many questions from patients asking us what happens...
Satellite Symposium – December 7, 2012 Chronic Myeloid Leukemia (CML): Evaluating the Evolving Therapeutic Landscape to Improve Outcomes Speakers: Neil Shah, MD, PhD, University of California...
The Issue: Although Canada has a relatively good Universal Healthcare program, this program is being eroded directly as a consequence of the high price of drugs and...
Thanks to our Friends Dr. Rob Rutledge and Dr. Timothy Walker for putting together this unique, over the internet ‘Skills for Healing’ workshop. What: The ‘Skills for...
SPRYCEL (™) (dasatinib) SPRYCEL (dasatinib) has been issued marketing authorization with conditions for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia...
Tasigna (™) (nilotinib) TASIGNA® is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. TASIGNA®...
TEVA-IMATINIB is indicated for the treatment of adult and pediatric patients with newly diagnosed Ph+ CML in chronic, accelerated or blast phase or after failure of interferon...
Thank you very much for taking the time to complete the survey! Importance of this Research This research is important because it helps to further our understanding...
The Chronic Myelogenous Leukemia (CML) Society of Canada is pleased to provide open access to the paper, “Treating Chronic Myeloid Leukemia – Improving Management Through Understanding of the Patient Experience”....
The majority of CML patients in Canada today are treated with oral tyrosine kinase inhibitors (TKI’s). There are currently (2015) seven TKI’s approved by health Canada for...
10/12/20: Patient group takes fight for access to cystic fibrosis medicines to the UN Human Rights Council Today is International Human Rights Day, the anniversary of the...
The CML Society of Canada is happy to announce that we have partnered with many CML Patient Advocate groups around the world with the help of The Max Foundation...
The CML Society of Canada is very pleased to recognize the work of the Province of Ontario for prioritizing equitable access to treatments for CML patients and...
Quality of Life II survey – The CML Society of Canada presented very preliminary findings from our Quality of Life II survey at the recent European School...
This is a report filed by our President, Mrs. Cheryl-Anne Simoneau from the Philadelphia Chromosome Conference. A conference celebrating the 50th anniverary of the discovery of the...
Please click on the following links to access some of the media coverage regarding the CML Society of Canada Interview – Tommy Schnurmacher show CJAD September 6,...
CML Headlines Working Towards a Cure in CML – Breakfast Satellite Symposium – CBMTG – April 2012, Toronto, Ontario – preview of Canadian CML Guidelines
Patient Navigational tools: Patient information brochures. Each brochure offers guidance on coping and management skills to help you on your journey with CML For the newly diagnosed:...
CML Glossary (and abbreviations) Richard Rockefeller, MD. Updated in 2015 by the CML Society of Canada. INTRODUCTION: Included here are terms specifically related to the disease of...
